Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xinxuening
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Xinxuening (心血宁胶囊) is a traditional Chinese patent medicine formulated as capsules, used primarily in China. It is indicated for patients with ischemic stroke who have elevated homocysteine levels (>15 μmol/L). The drug is designed to improve short-term functional outcomes in these patients. Xinxuening contains a combination of herbal ingredients, though the specific composition may vary by manufacturer and is not detailed in the available sources. Its mechanism of action likely involves modulation of vascular function and reduction of homocysteine-related vascular risk, but precise molecular targets are not specified.
- Brand names
- xinxuening
- Other names
- 心血宁胶囊
Beyond the preview
Go deeper on xinxuening.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xinxuening.